Pcdha: Homozygote x Homozygote; Olfr151: Homozygote x Homozygote; Cnga2: Heterozygote (female) x Wild-type (male) Pcdha: Homozygote x Homozygote; Olfr151: Homozygote x Homozygote; Cnga2: Heterozygote (female) x Wild-type (male) W9.5 [129S1/Sv-Oca2<+> Tyr<+> Kitl<+>] C（3〜6か月） STOCK Cnga2<tm1Mom> Olfr151<tm25Mom> Pcdha<tm3Tyag>/TyagRbrc STOCK Cnga2<tm1Mom> Olfr151<tm25Mom> Pcdha<tm3Tyag>/TyagRbrc OCNC1/M71-LacZ/BdAB OCNC1/M71-LacZ/BdAB 八木　健 Osaka Univ. C (3-6 months) <a href='https://brc.riken.jp/mus/pcr02139'>Genotyping protocol -PCR-</a> OCNC1 (Cnga2) knockout, CNR (Pcdha) delta CR mutant and M71 (Olfr151) gene ires-taulacZ knock-in triple mutant mice. 大阪大学大学院生命機能研究科・八木　健先生。CNR delta CR（AdAB）マウス（大阪大学大学院生命機能研究科・八木　健先生）（RBRC01688）とOCNC1 KOマウスとM71-lacZマウス（The Rockefeller University・Peter Monbaerts）との交配により育成。 条件を付加する。利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。<br>利用者は事前にThe Rockefeller University・Peter Monbaerts教授の許可を得る。本リソースを用いた研究が発明に至った場合、利用者はその発明を開示するとともに、取り扱いについて寄託者と協議する。また、利用者は本リソースを用いた研究を公表する際は事前に寄託者に内容を開示し許可を得る事。利用者が非営利目的の教育・研究用に用いる場合以外は、大阪大学と別途MTAを締結すること。 Takeshi YAGI OCNC1 (Cnga2) 遺伝子のノックアウト、CNR (Pcdha) 遺伝子の共通領域欠損 (PcdhaδCR) とM71 (Olfr151) 嗅覚受容体遺伝子座にires-taulacZを挿入した変異を持つトリプルミュータントマウス。 国立大学法人大阪大学 Developed by Takeshi Yagi, Graduate School of Frontier Biosciences, Osaka University. The mutant mice were generated by crossing with CNR delta CR (BdAB) (RBRC01688) (Takeshi Yagi, Graduate School of Frontier Biosciences, Osaka University) and OCNC1 KO and M71-lacZ mice (Peter Monbaerts, The Rockefeller University). Phage P1 loxP sites, mouse phosphoglycerate kinase promoter (PGK promoter), E. coli neo, Encephalomyocarditis virus (EMCV) internal ribosomal entry site (ires), E. coli lacZ, bovine tau cDNA, mouse Olfr151 genomic DNA, mouse Pcdha genomic DNA, mouse Cnga2 genomic DNA Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol><A HREF="https://www.fbs.osaka-u.ac.jp/labs/yagi/index.htm" target="_blank">Lab HP (Japanese)</A> RBRC02139 Cre/loxP system Neurobiology Research Fluorescent Proteins/lacZ System true Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior consent on use of it from Professor Peter Monbaerts, The Rockefeller University. If the RECIPIENT's research results in an invention based on the BIOLOGICAL RESOURCE, the RECIPIENT must contact DEPOSITOR to negotiate the treatment of such invention. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, the RECIPIENT must obtain a prior written consent from the DEPOSITOR. The RECIPIENT, which wishes to use the BIOLOGICAL RESOURCE for the purpose other than education or not-for-profit research, is requested to enter into a Material Transfer Agreement with Osaka University.